12:27 PM EDT, 04/01/2025 (MT Newswires) -- Valneva (VALN) said Tuesday the European Commission granted marketing authorization for the Ixchiq vaccine to prevent chikungunya in adolescents aged 12 and older.

The approval was based on data from a six-month Phase 3 study in Brazil, which showed that a single dose induced a high immune response in 99.1% of adolescents.

The company said Ixchiq is now approved for adults and adolescents in the European Union, alongside approvals in the US, UK, and Canada.

Shares of Valneva were up over 1% in recent trading.

Price: 6.79, Change: +0.08, Percent Change: +1.19